Concepts (47)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Small Cell | 1 | 2018 | 21 | 0.600 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 54 | 0.580 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 851 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 402 | 0.130 |
Why?
|
| Leukapheresis | 1 | 2015 | 8 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 11 | 0.120 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 10 | 0.120 |
Why?
|
| Liver Abscess | 1 | 2015 | 18 | 0.120 |
Why?
|
| alpha-Fetoproteins | 1 | 2015 | 15 | 0.120 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2015 | 32 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 68 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 94 | 0.110 |
Why?
|
| Prognosis | 1 | 2018 | 1597 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 276 | 0.100 |
Why?
|
| Isoquinolines | 1 | 2011 | 32 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 50 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5129 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 4273 | 0.070 |
Why?
|
| Aged | 4 | 2018 | 13426 | 0.070 |
Why?
|
| Adult | 4 | 2018 | 15695 | 0.070 |
Why?
|
| Middle Aged | 3 | 2018 | 16335 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 263 | 0.060 |
Why?
|
| Male | 4 | 2018 | 27775 | 0.050 |
Why?
|
| Female | 4 | 2018 | 30757 | 0.050 |
Why?
|
| Humans | 5 | 2018 | 59440 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2015 | 97 | 0.030 |
Why?
|
| Live Birth | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2015 | 37 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 116 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2015 | 95 | 0.030 |
Why?
|
| Vidarabine | 1 | 2011 | 6 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 46 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 57 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 80 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 284 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2011 | 201 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 179 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 603 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2215 | 0.020 |
Why?
|
| Capecitabine | 1 | 2007 | 10 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 38 | 0.020 |
Why?
|
| Camptothecin | 1 | 2007 | 23 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2007 | 40 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2007 | 56 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 228 | 0.020 |
Why?
|
| Survival Rate | 1 | 2007 | 801 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 5287 | 0.010 |
Why?
|